SLAS2018 International Conference and Exhibition - Insphero

SLAS2018 International Conference and Exhibition


Feb 03 - 07, 2018

Scalable 3D Technology Meets InSightful Biology

jump to section

Meet InSphero at SLAS2018, the annual meeting of the Society of Laboratory Automation & Screening, where science research and development professionals gather to learn about the latest and greatest laboratory tools and technologies available and how they are being applied by their peers. This year, InSphero scientists will be teaching short courses, leading tutorials, and giving scientific podium presentations. We’ll also be at Booth #1614 , ready to answer your questions about our:

  • Proven, cost-effective applications for pharma
  • Validated microtissue models engineered for better science
  • Scalable Akura™ platform exclusively for 3D InSight™ Microtisssues
 

Akura™ Flow:  SLAS2018 Innovation Award Top Candidate

Stop by our booth to get a preview of Akura Flow™ our new microphysiological system designed for body-on-a-chip applications such as low clearance assays and metabolic disease modeling using multiple types of 3D InSight™ microtissues. This technology is one of the top 10 contenders for the prestigious SLAS2018 Innovation Award.  We’re actively looking for partners to work with us on developing new applications using this powerful technology, designed to:

  • Minimize cell, medium and compound use in a miniaturized 10-microtissue configuration
  • Leverage maximum physiological complexity while minimizing operational complexity
  • Compare numerous conditions in parallel on one plate in a scalable, automation-compatible platform
  • Employ a diverse array of experimental endpoints

Conference Detail

  • Conference Dates: February 3-7, 2018
  • Booth: 1614

jump to section
jump to section

Oral Presentations

Short Course

Saturday, February 3, 8 AM – 3:15 PM; Location: 2
3D Cell-Based assays for Drug De-risking
Cell-based in vitro assays are used throughout the drug discovery and development chain, allowing for high throughput efficacy but also mechanistic-based toxicity testing. A big challenge however is the translation of in vitro assays towards the in vivo outcome. Physiological relevance is a key parameter to improve the predictive power of cell-based assays. The better we can reflect tissue architecture, composition and function the more predictive an in vitro assay will become. The 3D course covers advances in 3D cell culature technologies, assays and their use in drug discovery and development. Course instructors include InSphero Chief Scientific Officer Dr. Patrick Guye, and InSphero Head of Technology Platforms, Dr. Olivier Frey.

Exhibitor Tutorial

Tuesday, February 6, 9:30 – 10:15 AM; Location: Room 4
Leveraging Advanced 3D Models and Microphysiological Systems for More Physiologically Relevant Drug Discovery and Development
Complex human 3D tissue models for efficacy and toxicity screenings are becoming increasingly prevalent for efficiently de-risking and streamlining the drug discovery process. This tutorial covers the basics of implementing healthy and diseased human 3D microtissue models for applications such as toxicity testing, Steatotic/Fibrotic/NASH liver therapeutic agent efficacy assessments, diabetes modeling, as well as immuno-oncology applications with screening-compatible endpoints. Moreover, we will also address solutions for integrating these tissue models in automation-compatible body-on-a-chip/microphysiological systems. Aspects comprise: 3D microtissue models for disease modeling and efficacy testing, 3D microtissue models for safety testing, 3D microtissue models for target validation, and screening-compatible body-on-a-chip and microphysiological devices. Tutorial led by InSphero Chief Business Officer Dr. Frank Junker, Chief Scientific Officer Dr. Patrick Guye, and Head of Technology Platforms Dr. Olivier Frey.

Advances in Bioanalytics and Biomarkers Track

Monday, February 5, 4:30 – 5 PM; Location: 6E
Combining 3D liver microtissues with lipid loading and lipidomics as a screening model for non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, affecting all racial, ethnic, and age groups without sex predilection. characterized by an excessive accumulation of lipids in hepatocytes (steatosis) and in combination with inflammatory processes (NASH) progressively develops into end stage liver disease, NAFLD is a major clinical concern. Here, we describe a novel, screening-compatible human liver microtissue in vitro model for studying the etiology of steatosis and therapeutic strategies in a 3D configuration. The steatosis model is based on incubation with Oleate/Palmitate and displays a distinct and quantifiable accumulation of macro- and/or microvesicular lipid droplets within the hepatocytes. It maintains prolonged viability and liver-specific functionality in comparison to 2D cultures and can be produced in a 96-well SBS-compatible format. Presentation by InSphero Chief Scientific Officer Dr. Patrick Guye

Organ-on-a-Chip and Microphysiological Systems Session

Wednesday, February 7, 2 – 2:30 PM; Location: 7AB
Automating multi-tissue microphysiological systems using 3D microtissues
Complex human 3D tissue models for efficacy and toxicity screenings are becoming increasingly prevalent for efficiently de-risking and streamlining the drug discovery process. This tutorial covers the basics of implementing healthy and diseased human 3D microtissue models for applications such as toxicity testing, Steatotic/Fibrotic/NASH liver therapeutic agent efficacy assessments, diabetes modeling, as well as immuno-oncology applications with screening-compatible endpoints. Moreover, we will also address solutions for integrating these tissue models in automation-compatible body-on-a-chip/microphysiological systems. Aspects comprise: 3D microtissue models for disease modeling and efficacy testing, 3D microtissue models for safety testing, 3D microtissue models for target validation, and screening-compatible body-on-a-chip and microphysiological devices. Dr. Olivier Frey, InSphero Head of Technology Platforms, is the chair for this session in the Micro- and Nanotechnologies track.

Poster Presentations

Emerging Technology Poster

Monday – Wednesday; Location: Exhibit Hall, Booth 1614
Akura™ Flow: A Microfuidic Multi-tissue Platform Engineered for 3D InSight&trade Microtissues
The next step towards more biomimetic and systemic in vitro models is the design of multi-organ devices, which allow communication of different tissue types. InSphero’s multi-tissue platform features microfluidic channels and chambers that were specifically engineered for culturing of microtissue spheroids under physiological flow conditions. The Akura™ Flow system has a plate-format, is produced completely out of polystyrene, and complies with SBS-standard dimensions for automation. The concept allows on-demand interconnection of up to 10 same or different microtissues per channel in a very flexible way. With the broad range of available spheroid-based organ-models, near unlimited pre-clinical testing applications can be generated using the very same platform.